Menetelmä oligonukleotidianalogien valmistamiseksi, joista on muodostettu 3'-johdannaisia ja joissa on ei-nukleotidisiä ryhmiä ja niiden käyttö
Oligonucleotide analogs (I) and their physiologically tolerable salts. Oligonucleotide analogs and their physiologically tolerable salts of formula (I) are new. R = H, a substituent or -P(=W)ZZ'; R = H, OH, 1-18C alkoxy, halo, azido or amino; B = nucleotide base residue; A = oxy or methylene; d...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | Finnish Swedish |
Published |
31.03.2005
|
Edition | 7 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Oligonucleotide analogs (I) and their physiologically tolerable salts. Oligonucleotide analogs and their physiologically tolerable salts of formula (I) are new. R = H, a substituent or -P(=W)ZZ'; R = H, OH, 1-18C alkoxy, halo, azido or amino; B = nucleotide base residue; A = oxy or methylene; d, e, f = 0-50; i = 1-10; r = 0 or 1; W = oxo, selenoxo or thioxo; V = oxy, sulfandiyl or imino; Y = oxy, sulfandiyl, imino or methylene; Y' = oxy, sulfandiyl, imino, (CH2)m or V(CH2)m; m = 1-18; X = OH or SH; U, R , R = substituents; p = 1-100; q = 0-18; R = H or functional group; Sp = a (3',5'-) spacer group of formula (i); g, g' = 0 or 1; h = 0-10; G = 1-12C alkylene (optionally substituted), (6-14C)aryldi-(1-8C)alkylene, 6-18C arylene, (CH2CH2V) alpha CH2CH2, (CH2V) alpha CH2, -(G-Y-P(=W)(U)-Y'-) beta or a group of formula (ii); alpha = 1-11; beta = 1-6; Z, Z' = OH, (seleno)thio or a substituent; provided that r is 0 when V is Y' and is 1 if i is greater than 1. Positions of R and the adjacent phosphoryl residue can be reversed; each nucleoside had D- or L-configuration and each B has alpha or beta configuration. Independent claims are also included for: (1) a method for producing (I); (2) the phosphitylation reagent of formula DMTr-X'-G'-Y''-P(U')(NR R ); and (3) a pharmaceutical composition containing at least one compound (I) and optionally auxiliary, carrier and/or other active agents. R , R = 1-12C alkyl or together form a 5-6 membered ring; DMTr = dimethoxytrityl; X', Y'' = oxy or sulfandiyl; U' = 1-4C alkyl or protected OH; G' = (CH2CH2O) alpha CH2CH2 or CH2CH(OR')CH2; and R' = 1-18C alkyl, 6-14C aryl or 6-14C aryl(1-8C) alkyl. |
---|---|
AbstractList | Oligonucleotide analogs (I) and their physiologically tolerable salts. Oligonucleotide analogs and their physiologically tolerable salts of formula (I) are new. R = H, a substituent or -P(=W)ZZ'; R = H, OH, 1-18C alkoxy, halo, azido or amino; B = nucleotide base residue; A = oxy or methylene; d, e, f = 0-50; i = 1-10; r = 0 or 1; W = oxo, selenoxo or thioxo; V = oxy, sulfandiyl or imino; Y = oxy, sulfandiyl, imino or methylene; Y' = oxy, sulfandiyl, imino, (CH2)m or V(CH2)m; m = 1-18; X = OH or SH; U, R , R = substituents; p = 1-100; q = 0-18; R = H or functional group; Sp = a (3',5'-) spacer group of formula (i); g, g' = 0 or 1; h = 0-10; G = 1-12C alkylene (optionally substituted), (6-14C)aryldi-(1-8C)alkylene, 6-18C arylene, (CH2CH2V) alpha CH2CH2, (CH2V) alpha CH2, -(G-Y-P(=W)(U)-Y'-) beta or a group of formula (ii); alpha = 1-11; beta = 1-6; Z, Z' = OH, (seleno)thio or a substituent; provided that r is 0 when V is Y' and is 1 if i is greater than 1. Positions of R and the adjacent phosphoryl residue can be reversed; each nucleoside had D- or L-configuration and each B has alpha or beta configuration. Independent claims are also included for: (1) a method for producing (I); (2) the phosphitylation reagent of formula DMTr-X'-G'-Y''-P(U')(NR R ); and (3) a pharmaceutical composition containing at least one compound (I) and optionally auxiliary, carrier and/or other active agents. R , R = 1-12C alkyl or together form a 5-6 membered ring; DMTr = dimethoxytrityl; X', Y'' = oxy or sulfandiyl; U' = 1-4C alkyl or protected OH; G' = (CH2CH2O) alpha CH2CH2 or CH2CH(OR')CH2; and R' = 1-18C alkyl, 6-14C aryl or 6-14C aryl(1-8C) alkyl. |
Author | HELSBERG,MATTHIAS WINKLER,IRVIN PEYMAN,ANUSCHIRWAN O'MALLEY,GERARD JOSEPH UHLMANN,EUGEN |
Author_xml | – fullname: HELSBERG,MATTHIAS – fullname: PEYMAN,ANUSCHIRWAN – fullname: UHLMANN,EUGEN – fullname: WINKLER,IRVIN – fullname: O'MALLEY,GERARD JOSEPH |
BookMark | eNqFjj0OglAQhCm08O8Mvs5GCiRcACPRws6ebGSFhccu8T1MuIdH4AxegIv5MCaWNjOZ5MvMzL0JC-PMe56R0aKuh16Jply4rTSKpYyAQUtOyOoBuiZjwQlWhraqlDEqYVW3komxaG2rwo1fSpEBM5AhUCV8QPMBkfxftSE3d--KenSHMVHmdqqh76wdXktvegNtcPX1hbdODpf90cdGUjQNXMfTaXIKgmgXRHEc_ifexx1WHg |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | Förfarande för framställning av 3'-derivatiserade oligonukleotidanaloger med icke-nukleotida grupper och deras användning |
Edition | 7 |
ExternalDocumentID | FI115215BB |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_FI115215BB3 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 14:18:37 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | Finnish Swedish |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_FI115215BB3 |
Notes | Application Number: FI19930000221 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20050331&DB=EPODOC&CC=FI&NR=115215B |
ParticipantIDs | epo_espacenet_FI115215BB |
PublicationCentury | 2000 |
PublicationDate | 20050331 |
PublicationDateYYYYMMDD | 2005-03-31 |
PublicationDate_xml | – month: 03 year: 2005 text: 20050331 day: 31 |
PublicationDecade | 2000 |
PublicationYear | 2005 |
RelatedCompanies | HOECHST AKTIENGESELLSCHAFT |
RelatedCompanies_xml | – name: HOECHST AKTIENGESELLSCHAFT |
Score | 2.620625 |
Snippet | Oligonucleotide analogs (I) and their physiologically tolerable salts. Oligonucleotide analogs and their physiologically tolerable salts of formula (I) are... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES DERIVATIVES THEREOF ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING NUCLEIC ACIDS NUCLEOSIDES NUCLEOTIDES ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS SUGARS VINEGAR WINE |
Title | Menetelmä oligonukleotidianalogien valmistamiseksi, joista on muodostettu 3'-johdannaisia ja joissa on ei-nukleotidisiä ryhmiä ja niiden käyttö |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20050331&DB=EPODOC&locale=&CC=FI&NR=115215B |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdR3LTsJAcINo1JuiBt97MPViI7UtaQ-NSVsaMOERg4YbWWgLy2NL6DaG__AT-AZ_gB9zdgPihUv3NZltZzs7s4-ZQejBCO0oDM0YWFyEMCNhWbXDqKT2rTgGBVvvadJ9cb1Rrn4Ybx2zk0ODjS2M9BP6JZ0jAkf1gd-5nK9n200sX96tTJ97FKqS16Dt-MpmdSwO5TTFd51Kq-k3PcXznKCmNN4dTcgp091D-6BDW-LuX-XTFSYps__yJDhBBy1AxfgpysW0gI68Tdi1Ajqsr0-7IbtmvPQMfdfFO0aT6WqJkwkdJCwbT6KEUzG8Yv8FADH8NAILgUc0TukTHiWiiBOGpxksP2FAOc-w_qiOkmFIGCM0pQSPiARMJWBE1S3qlEJ388VwKlIAY1SEIMXj1XLB-ernHN0HlbZXVeHzun-E7Aa1NRlc_QLlWcKiIsJ2z-5rsRXr0GCAfkI00Ao0g1iQL73E5iUq7sJytbvpGh1LJ6fSeu8G5fk8i25BfPPenST9L6XWp00 |
link.rule.ids | 230,309,786,891,25585,76894 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3NTsJAEN4gGvGmqMFf9mDqxUZqW0IPjUlbGlAKxKDhRlrawvKzJXSJ4T18BJ7BF-DFnN2AePHS7nYn0-1OpzO72_kGoTstNKIw1GNQcZ7CzA_LshFGJblfiWNwsNVAEfDFXrNce9deuno3gwbbWBiBE_opwBFBo_qg70x8r2e7RSxH_FuZPgYELiXPbsd0pO3smG_KKZJjmdV2y2nZkm2bbl1qvpkKt1O6tYf2wb82OMh-9cPiISmzv_bEPUYHbWBF2QnKxCSPcvY27VoeHXqb3W4obhQvPUVfHu9jNJmuVziZkEFCF-NJlDDCxcvXX4AQw0vDufhwiMYpecCjhFdxQvF0AdNPEChjC6zey6NkGPqU-iQlPh75gjAVhBGRd6xTArebL4dTfgYySngKUjxer5aMrb_PUNGtduyaDI_X-x3InlvfDIOlnqMsTWhUQNgIjL4SV2IVGjTwT3wFvAJF8ytQLj3F-gUq_Mfl8v-mIsrVOl6j16g3X6_QkQA8FZF81yjL5ovoBkw5C26FGH4ArOSqQA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Menetelm%C3%A4+oligonukleotidianalogien+valmistamiseksi%2C+joista+on+muodostettu+3%27-johdannaisia+ja+joissa+on+ei-nukleotidisi%C3%A4+ryhmi%C3%A4+ja+niiden+k%C3%A4ytt%C3%B6&rft.inventor=HELSBERG%2CMATTHIAS&rft.inventor=PEYMAN%2CANUSCHIRWAN&rft.inventor=UHLMANN%2CEUGEN&rft.inventor=WINKLER%2CIRVIN&rft.inventor=O%27MALLEY%2CGERARD+JOSEPH&rft.date=2005-03-31&rft.externalDBID=B&rft.externalDocID=FI115215BB |